Our offices across 12 countries and 3 continents all share the same vision. Your achievement is the reason for our existence and your growth is our passion.
China’s Logistics Industry Prepares for COVID-19 Vaccine Distribution
Share
China is developing cross-border medical cold chain facilities to prepare for the distribution of COVID-19 vaccines to other countries, with developing nations on the priority list.
China is joining the race to develop COVID-19 vaccines with five candidates from four different companies going through phase-3 trials. During the pandemic, China’s logistics industry has already played a significant role in transporting medical supplies globally. However, the transportation of vaccines needs a smooth cold chain logistics system to maintain the required temperature throughout the full supply chain. Compared to some other developed countries, the cold chain industry in China is still in the developing stage. Nevertheless, the cold chain industry in China shows significant growth, increasing from a total market value of 94.4 billion RMB (12.4 billion USD) in 2012 to 310.1 billion RMB (47.5 billion USD) in 2020, a CAGR of 16.3%. It is projected to reach 512.1 billion RMB (78.4 billion USD) in 2026, a projected CAGR of 9.4% between 2020 and 2026.
Recently, the industry took a step further to enhance its cold-chain capabilities to transport temperature-controlled medicine, including COVID-19 vaccines. Cainiao, a logistics company under the Chinese giant Alibaba, has cooperated with Ethiopian Airlines to open the first regular cold-chain air freight service in China, which will enable the transportation of COVID-19 vaccines to Africa and the Middle East. Besides, Cainiao also partnered with Shenzhen International Airport, a certified unit for pharmaceutical logistics by the International Air Transport Association. The airport has several climate-controlled rooms with real-time temperature monitoring systems, occupying a total area of 350 square meters. From there, vaccines will be shipped to the cargo terminal in Ethiopia which is also equipped with temperature control systems. This end-to-end cold chain route can handle temperatures as low as minus 23 degrees Celsius.
Another Chinese logistics company, SF Express, is also working with suppliers to help transport vaccine candidates and semi-finished items for clinical trials between China and other countries. It has prepared over 200 specialized vehicles for transporting cold chain medical products, cold storage in 11 cities across the country, and temperature-controlled boxes for the COVID-19 vaccines.
In conclusion, the effort to build an end-to-end cross-border cold chain solution to support vaccine transportation of Chinese logistics companies is a remarkable achievement of the industry driven by the goodwill to make vaccines accessible and affordable to developing countries. Amidst the current pandemic, China has quickly grasped the opportunity to exponentially grow its cold chain industry while positively contributing to the eradication of the COVID-19.
Read more about our sourcing & supply chain management expertise or other consulting services.
Share
Subscribe to New Articles and ARC Group Updates
Receive our latest market insights, news and reports, and business bulletins.
Executive Summary State Council Decree No. 837 (effective July 1, 2026) establishes a security-focused legal framework that reshapes outbound M&A. It does not ban consumer sector deals, but it changes how they must be structured, approved, and integrated. Expansion of Regulatory Scope: Individual Investors and Indirect Structures Brought into the Compliance Scope Resident individuals are, […]
Overview Corporate AI has settled into a familiar pattern: broad use, thin value. Close to 90% of companies now use AI routinely in at least one business function, yet only a handful have turned that into value at enterprise scale. The bottleneck is not the technology. It is the organization. At its core, AI transformation […]
Most companies approach an IPO as a milestone. In reality, it is a reset. The valuation is set, the story is told, and the stock begins trading. From that point onward, the market is no longer pricing potential. It is pricing delivery. The most critical period is often the six to eighteen months that follow, […]
Subscribe to New Articles and ARC Group Updates
Receive our latest market insights, news and reports, and business bulletins.
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.